[与利培酮相比，癸酸氟哌噻吨治疗期间强直的发生率]
[Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone].
作者信息
Scherer Josef, Dobmeier Peter, Kuhn Karin, Schmaus Werner
机构信息
Klinik des Bezirks Oberbayern am Klinikum Garmisch-Partenkirchen.
出版信息
Psychiatr Prax. 2004 Nov;31 Suppl 1:S167-9. doi: 10.1055/s-2004-828461.
STUDY OBJECTIVE
We investigated as to whether dosedependent extrapyramidal tolerance of Flupentixol decanoate is inferior to that of Risperidone.
METHOD
143 Risperidone and 177 Flupentixol decanoate treated patients were consecutively entered into this non - randomized open study and assessed with the Simpson-Angus-Scale regarding presence of rigor. Treatment comparisons of rigor frequency was done by Kaplan-Meier analysis.
RESULTS
The risk of rigor increased with dose on both treatments. EPMS-risk was not increased under treatment with Flupentixol decanoate (mean dose 35.06 +/- 19.7 mg/2 weeks) compared to Risperidone (mean daily dose: 5.2 +/- 2.5 mg/kg) when comparable weight standardized Haloperidol equivalence doses (WHE) were used.
CONCLUSION
This study offers limited evidence for methodological reasons. Yet, results do not support the view that EPS are more frequent on Flupentixol decanoate than on Risperidone when doses are comparable.
研究目的
我们调查癸酸氟哌噻吨的剂量依赖性锥体外系耐受性是否低于利培酮。
方法
143例接受利培酮治疗的患者和177例接受癸酸氟哌噻吨治疗的患者连续纳入这项非随机开放研究，并使用辛普森-安格斯量表评估是否存在强直。强直频率的治疗比较采用Kaplan-Meier分析。
结果
两种治疗中强直风险均随剂量增加而增加。当使用相当的体重标准化氟哌啶醇等效剂量（WHE）时，与利培酮（平均日剂量：5.2±2.5mg/kg）相比，癸酸氟哌噻吨（平均剂量35.06±19.7mg/2周）治疗下的EPMS风险并未增加。
结论
由于方法学原因，本研究提供的证据有限。然而，结果并不支持在剂量相当的情况下，癸酸氟哌噻吨的锥体外系反应比利培酮更频繁的观点。
Zotero 插件